CellRapeutics™ Cytokine Release Test Service

Are you currently facing complex challenges in developing safe and effective cell therapies, such as the unpredictable and potentially life-threatening risks of cytokine release syndrome (CRS) and neurotoxicity? Creative Biolabs' CellRapeutics™ Cytokine Release Test Service offers a comprehensive solution to identify and characterize the cytokine profile of your therapeutic candidates, helping you mitigate these critical safety concerns and accelerate your biopharmaceutical development pipeline.

Introduction

The advent of CAR-T cell therapy has redefined the oncological treatment landscape, yet its clinical dividend is frequently curtailed by dose-limiting toxicities, most prominently CRS and immune-effector-cell–associated neurotoxicity syndrome (ICANS). These adverse events originate from the explosive, cascade-like liberation of pro-inflammatory cytokines such as IL-6, IFN-γ, triggered when CAR T cells engage and lyse their target cells, culminating in a systemic inflammatory storm. Owing to the unpredictable kinetics and potentially fatal trajectory of such toxicities, rigorous quantification and detailed characterization of CAR T-cell–derived cytokine release are indispensable for safeguarding therapeutic candidacy.

Fig.1 Key drivers of cytokine release syndrome.¹

CellRapeutics™ Cytokine Release Test Service at Creative Biolabs

Creative Biolabs' CellRapeutics™ cytokine release test service focuses on the unique biological properties of γδ T cells and utilizes advanced technologies to engineer bespoke CAR-γδ T, which delivers accurate tumor targeting and potentiated therapeutic efficacy. Our service provides fully tailored design strategies coupled with rigorous in vitro and in vivo validation, accelerating your research from concept to clinical candidate.

What we can offer

Creative Biolabs offers a comprehensive portfolio of highly sensitive and robust assays designed for the precise quantification of cytokine release, which is essential for evaluating the safety and efficacy profiles of CAR-T cell therapies across all stages of the development pipeline.

Our Service Process

Our CellRapeutics™ service follows a meticulous, multi-step workflow designed for clarity and scientific rigor.

Required Starting Materials:

• Your therapeutic candidate (such as CAR T-cells, TCR T-cells, or other immune effector cells).
• A target cell line or primary cell population (such as tumor cells, or other antigen-expressing cells).
• Relevant control cells for baseline comparison (such as mock-transduced cells or non-specific T cells).

Key Steps Involved:

Final Deliverables:

• A comprehensive project report summarizing the study design, methods, and key findings.
• Detailed raw data files from experiments.

Key Advantages

• Exceptional Sensitivity: Our assays are capable of quantifying minute concentrations of cytokines, enabling the detection of subtle fluctuations in cytokine profiles with high precision.
• Standardized and Rigorous Protocols: All assays are performed using strictly standardized and validated procedures to guarantee highly reproducible and dependable results.
• Deep-Seated Expertise: Our specialized team possesses extensive experience in cytokine analysis and CAR-T cell therapy development, ensuring expert guidance and superior service tailored to each client's needs.

FAQ

Why Choose Us?

As a leader in preclinical safety assessment, Creative Biolabs has advanced technology and extensive expertise, delivering a comprehensive cytokine release test service. Our robust testing platform generates reliable and reproducible data, empowering you to make confident and critical go/no-go decisions throughout your development process.

Customer Reviews

"Using Creative Biolabs' CellRapeutics™ Cytokine Release Test Service in our research has significantly improved our ability to predict potential clinical toxicities. The detailed analysis of IL-6, IFN-γ and IL-10 levels gave us the confidence to move our candidate forward, avoiding the pitfalls we'd seen with other labs." Jm P**er.

"Creative Biolabs' platform provided a side-by-side cytokine profile that clearly demonstrated our product's lower inflammatory potential. The data was clear, concise, and incredibly useful for our regulatory submission." Aa M*n.

"The detailed analysis from Creative Biolabs helped us understand the underlying mechanism of a previously observed off-target effect and allowed us to adjust our molecular design. The technical support was outstanding and provided key recommendations for our project's success." Ty W*s.

How to contact us?

Creative Biolabs serves as your trusted scientific partner to address the complexities of cell therapy development. Our CellRapeutics™ Cytokine Release Test Service represents a critical element for ensuring both success and safety in your program.

To learn more about how our service can support your specific project or to request a detailed quotation, please contact our team using the link provided below.

Experience the Creative Biolabs Advantage - Get a Quote Today

Reference

1. Xiao, Xinyi et al. "Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies." Journal of experimental & clinical cancer research: CR vol. 40,1 367. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2024.1389971.